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Abstract
The activation of dopamine (DA) neurotransmission plays a crucial role in the behavioral
responses to drugs of abuse. In particular, increased extracellular levels of DA within the
mesolimbic pathway have been implicated in the rewarding and locomotor stimulatory properties
of morphine. We investigated the behavioral responses to morphine in mice with a genetic
disruption of the DA transporter (DAT), resulting in a constitutively high level of extrasynaptic
DA. In the conditioned place preference test, DAT-/- mice exhibited a stronger rewarding
response to morphine (5 mg/kg, s.c.) compared to control littermates. However, the same dose of
morphine failed to increase locomotor activity in DAT-/- mice, while enhancing locomotion in
DAT+/- and DAT+/+ animals. Morphine-induced analgesia was unaffected in mutant mice, but the
behavioral expression of naloxone-induced withdrawal signs was blunted. In vivo voltammetry in
the shell of the nucleus accumbens revealed that morphine was able to stimulate DA neurons in
DAT-/- mice, resulting in the accumulation of higher extracellular DA levels compared to control
animals. Morphine also induced a higher rate of c-fos transcription in the shell of the nucleus
accumbens in mutant mice. We conclude that morphine-induced rewarding responses are firmly
established in DAT mutant mice despite a DA transmission that is already tonically activated, and
independently of any effect on locomotion. These particular behavioral responses to morphine
may be associated with the action of the drug on DA release and c-fos expression in the shell of
the nucleus accumbens of DAT -/- mice.
Introduction
Morphine and related opioids increase nigrostriatal and mesolimbic dopamine (DA) turnover,
metabolism and release (Di Chiara & Imperato, 1988; Di Chiara & North, 1992). In the ventral
tegmental area, morphine indirectly stimulates the firing of DA neurons by inhibiting GABAergic
neurons that normally hold the mesolimbic DA system under an inhibitory control (Matthews &
German, 1984; Johnson & North, 1992; Klitenick et al., 1992). The resulting activation of DA
release in the nucleus accumbens appears to be critically involved in the rewarding and locomotor
stimulant responses to morphine (Wise & Bozarth, 1987; Wise & Rompre, 1989; Koob, 1992;
Nestler et al., 1993; Di Chiara, 1995), although DA-independent mechanisms have also been
postulated (Ettenberg et al., 1982; Kalivas et al., 1983; Pettit et al., 1984; Mackey & Van Der
Kooy, 1985; Stinus et al., 1985). Despite this controversy, there is ample evidence indicating that
activation of DA transmission is crucial in the development of opioid addiction, as reported in the
syndrome of morphine abstinence, individual vulnerability to seek opioid drugs and relapse after a
period of abstinence (Koob & Bloom, 1988; Koob & Le Moal, 1997; Nestler & Aghajanian,
1997; Self, 1998).
In the present study, we investigated the participation of DA neurotransmission in the
behavioral responses to morphine in a strain of mice genetically modified to disrupt the DA
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transporter (DAT) gene (Giros et al., 1996). The DAT plays a central role in determining the
duration and amplitude of DA action by rapidly recapturing extracellular DA into presynaptic
terminals after release (Horn, 1990; Giros & Caron, 1993). DAT-/- mice are thus characterized by
a DA-deficient but functionally hyperactive mode of DA neurotransmission, which is expressed by
constitutively high levels of extracellular DA, depleted intracellular DA stores and spontaneous
locomotor hyperactivity when placed in a novel environment (Giros & Caron, 1993; Jones et al.,
1998).
Two recent studies showed that the lack of the DAT gene did not prevent the expression of
the reinforcing properties of cocaine in DAT-/- mice, investigated either under a place preference
paradigm (Sora et al., 1998) or a self-administration protocol (Rocha et al., 1998), although it
abolished the locomotor stimulant property of the drug (Giros et al., 1996). These findings were
unexpected, as pharmacological data strongly suggested that the DAT is the main target for the
reinforcing properties of cocaine (Kuhar et al., 1991).
In the present study, we investigated the behavioral responses of DAT-/- mice to morphine.
In particular, we studied whether the rewarding, locomotor stimulatory, analgesic and withdrawal
responses to morphine were still present in these mice with profound changes in DA transmission
activity. In addition, in vivo voltammetry, c-fos mRNA in situ hybridization and µ opioid receptor
autoradiography were performed to try to elucidate the mechanisms implicated in the behavioral
responses to morphine in DAT-/- mice.
Materials and Methods
Animals
Homozygous DAT-/- mice were obtained by genetic manipulation as described (Giros et al., 1996).
These mice were then backcrossed for more than 2 years (12 generations) on a C57BL/6
background. DAT-/-, heterozygous DAT+/- and wild-type DAT+/+ littermates were obtained from
the mating of DAT+/- mice. Before the experiments, the genotype of the mice was determined by
Southern (DNA) blot analysis as previously described (Giros et al., 1996). All animals used in the
experiments were drug-naive. When not stated otherwise, experiments were conducted during the
light phase of the light/dark cycle (7:30-19:30). Behavioral and pharmacological studies were
performed in a soundproof room by an observer who knew neither the genotype of the mice nor
the pharmacological treatment. All experiments were conducted in accordance with standard
ethical guidelines (European Communities Council Directive for the care and use of laboratory
animals) and approved by the local ethical committee.
Drugs
Morphine-HCl (Sigma, St-Louis, Missouri, USA) was administered at a dose of 5 mg/kg, s.c. in all
the experiments, except in the test of morphine abstinence (see below). This dose has been
previously shown to induce an hyperlocomotor response (Matthes et al., 1996; Maldonado et al.,
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1997) and intense rewarding effects in the place-conditioned paradigm, which do not increase
when using higher doses of morphine (Maldonado et al., 1997). Naloxone-HCl (Sigma) was
administered at the dose of 1 mg/kg, s.c.
Conditioned place preference test
Apparatus . The place preference apparatus consisted of a Plexiglas box divided into two
compartments (15x15x15 cm), separated from each other by a neutral area of 8 cm. The box was
located in a soundproof testing room with white noise to further mask external noises and
illuminated by two 20 W indirect lights. Three distinctive sensory cues differentiated the
compartments: the wall and floor coloring (black or stripes), the floor texture (rough or smooth)
and the odor (wood or nothing). The combination was as follows: a) black wall, rough floor, no
smell added; b) striped wall, smooth floor, wooden smell. The neutral area providing access to the
compartments had gray walls and floor.
Procedure. One compartment of the place preference apparatus was randomly chosen to be paired
to drug administration and the other to saline (unbiased paradigm) (Valverde et al., 1995). The
place preference conditioning schedule consisted of three phases. 1) Pre-conditioning phase, during
which mice were placed in the middle of the neutral area and their location was recorded for 18
min. After the session, animals were randomized to receive drug or vehicle administration and were
assigned to one of the compartments. 2) Conditioning phase, during which mice were treated for
eight consecutive days with alternate injections of morphine (5 mg/kg, s.c.) or saline. Doors
matching the walls of the compartment allowed the confinement of the mice for 20 min
immediately after the injection. Mice were injected with the drug on days 1, 3, 5 and 7 and vehicle
on days 2, 4, 6 and 8. Controls received vehicle every day. 3) The testing phase took place 24 h
after the final conditioning session, and was conducted exactly as the pre-conditioning phase, with
free access to each compartment for 18 min, in the absence of drug administration.
Locomotor activity
Apparatus. Locomotion was evaluated in transparent activity boxes (20x15x25 cm) under low
illumination (<5 lux). Displacements were measured by photocell beams located across the long
axis, 20 mm (horizontal activity) and 60 mm (vertical activity) above the floor (Immetronic,
Bordeaux, France).
Procedure. The acute locomotor stimulant properties of morphine were evaluated by injecting
morphine (5 mg/kg, s.c.) or saline 10 min prior to the introduction of the mice into the activity
boxes. The session lasted 10 min. In a second experiment, locomotion was measured for five
consecutive days, from 8:30 to 18:30. The first three days consisted of an habituation phase
without any pharmacological treatment. The two following days, mice were placed in the activity
boxes and injected with saline on day 4 or with morphine (5 mg/kg, s.c.) on day 5, 8 h after the
beginning of the session. In the third experiment, locomotor reactivity to a natural stimulus was
measured at the time of light to dark transition (19:30), in mice which had been habituated to the
activity boxes for 48 h, with food and water available ad libitum.
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Morphine-induced analgesia
Tail-immersion (54°C) and hot-plate (52°C) tests were performed 30 min after the injection of
saline or morphine (5 mg/kg, s.c.). The cut-off time was 10 s for the tail-immersion test, and 30 s
and 240 s for licking and jumping responses in the hot-plate test, respectively.
Morphine-induced physical dependence
Opiate dependence was induced by repeated i.p. injection of morphine, every 12 h, for six days.
The use of intermittent injections of morphine has been widely reported to induce a similar degree
of opioid dependence to that produced by implanted minipumps (for review, see (Maldonado et al.,
1996), and has the advantage of not requiring surgery, a relevant issue when using fragile animals
such as DAT-/- mice. The dose of morphine was progressively increased as follows: day 1, 10
mg/kg; day 2, 20 mg/kg; day 3, 30 mg/kg; day 4, 40 mg/kg; day 5, 50 mg/kg; day 6 (only one
injection in the morning), 50 mg/kg. Control mice were treated with saline under the same
conditions. Withdrawal was precipitated by injecting naloxone (1 mg/kg, s.c.) 2 h after the last
morphine administration. Thirty min before naloxone injection, mice were placed individually
into transparent round test chambers (30 cm in diameter, 50 cm in height). The behavioral signs
of withdrawal were evaluated during 30 min before and 30 min after naloxone injection. Only the
behavioral observations obtained after naloxone injection are presented. The number of wet dog
shakes, jumping, paw tremor and sniffing were counted. Teeth-chattering, diarrhea, tremor and
ptosis were evaluated over 5-min periods, one point being given for the presence of each sign
during each period. The number of periods showing the sign was then counted (maximum score of
6).
In vivo voltammetry
Mice were treated with pargyline (75 mg/kg, i.p.), an inhibitor of monoamine oxydase, and
anaesthetized with urethane (1.15 g/kg, i.p.) 30 min later. The head was positioned in a
stereotaxic frame using a mouse adaptor (Stoelting, Wood Dale, Illinois, USA). Carbon fiber
electrodes with an active surface of 8 µm in diameter and 250 µm long were treated
electrochemically as described (Suaud-Chagny et al., 1992), except for the amplitude of the first
treatment. Since sensitivity and linearity for DA depend on this amplitude, it was set at 2.5 V for
DAT-/- mice and at 2.65 V for DAT+/+ and DAT+/- mice. After opening of the skull, the dura
mater was punctured with an used electrode at the following coordinates: 1.2 mm anterior t o
bregma and 0.6 mm lateral (Paxinos & Franklin, 1996). A freshly-treated carbon fiber electrode
was implanted through this hole at a depth of 4.25 mm below the cortical surface, in the nucleus
accumbens shell (AcbSh). The catechol oxidation peak appearing at +85 mV was recorded every
90 s with differential normal pulse voltammetry using a three-electrode system (Suaud-Chagny et
al., 1992). Baseline activity was recorded for 30 min, followed by the injection of morphine (5
mg/kg, s.c.) and the recording was continued for 120 min.
To record the DA overflow following electrical stimulation, a slightly different protocol was
used. Mice were anaesthetized with urethane (1.3 g/kg, i.p.) without pargyline treatment and fixed
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in a stereotaxic frame as indicated. The medial forebrain bundle (MFB) was electrically stimulated
using a bipolar concentric electrode with current pulses (amplitude: 300 µA and duration: 0.5 ms)
at the following coordinates: 2 mm posterior to bregma and 0.7 mm lateral. The depth was
adjusted in each experiment to maximize the DA overflow (Dugast et al., 1994). Carbon fiber
electrodes were implanted in the AcbSh as described above and held at +0.4 V versus a Ag/AgCl
reference electrode. The variations in the oxidation current were continuously recorded and
digitized as described (Dugast et al., 1994). The variations evoked by MFB stimulation were
entirely due to DA overflow in the extracellular fluid, resulting from stimulated DA release minus
DA elimination. They were estimated in terms of DA concentration by in vitro calibration after
in vivo recordings (Dugast et al., 1994).
In situ hybridization and autoradiography experiments
For in situ hybridization of c-fos mRNA expression, DAT+/+ and DAT-/- mice were injected with
a single dose of morphine (5 mg/kg, s.c.) and were sacrificed by decapitation one hour after the
injection. Brains were removed, frozen in liquid nitrogen and cut into coronal sections (12 µm)
which were stored at -80°C until use. The in situ hybridization was performed with cRNA probes
labeled with [35S]UTP (New England Nuclear, Hounslow, UK) as described (Le Moine et al.,
1997). Sections were exposed at room temperature to X-ray films (Kodak Biomax) for three
weeks.
For autoradiography studies of µ opioid receptors, brains of DAT+/+ and DAT-/- mice were
removed, frozen in liquid nitrogen and cut into cryostat sections (12 µm). FK-33824 (Sandoz,
Basel, Switzerland), a µ receptor agonist, was radioiodinated and purified as described (Jordan et al.,
1996), at a specific activity of 400 Ci/mmol. Sections were warmed to room temperature and
incubated at 25°C for 60 min in 50 mM Tris-HCl pH 7.4, containing 0.5% bovine serum albumin
and 0.5 nM [125I]-FK-33824. The µ receptor agonist [D-Ala2, Gly-o15] enkephaline (DAGO), 1
mM, was used to determine non-specific binding. At the end of the incubation period, the sections
were washed three times in ice-cold buffer without bovine serum albumin. Sections were then dried
and apposed to tritium-sensitive film for 24 h. The resulting autoradiograms were analyzed by
densitometry using a Biocom RAG 200 analysis system (Biocom, Les Ulis, France), together with
brain paste standards. Optical density was converted to nCi/mg protein using the standard curve.
Statistical analysis
For the behavioral experiments, analyses of variance (ANOVA) were used to compare the
distribution of the values between groups. Post-hoc individual comparisons were made using the
Student’s t-test. The results of in vivo voltammetry, autoradiography and in situ hybridization
were analyzed with ANOVA, followed by post-hoc Newman-Keuls test. All data are presented as
mean ± SEM.
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Results
Morphine-induced conditioned place preference
During the pre-conditioning phase, DAT-/- mice and their control littermates visited the two
compartments of the place preference apparatus and no difference was observed in the time spent
in each compartment (not shown). Morphine administration (5 mg/kg, s.c.) induced a clear
conditioned place preference in the three groups, indicated by a significant increase in the time
spent in the drug-associated compartment during the post-conditioning phase (Figure 1A). Figure
1B shows the results expressed as a score, i.e., post-conditioning minus pre-conditioning time
spent in the drug-associated compartment. A two way ANOVA using the score as the dependent
variable indicated a treatment effect [F(1,70)=20.12, p<0.0001] and a genotype x treatment
interaction [F(2,70)=3.44, p<0.04,] but not a genotype effect. A subsequent one-way ANOVA
performed in morphine-treated mice showed that the score was significantly greater in the
DAT-/- mice as compared to DAT+/+ and DAT+/- mice [genotype effect: F(2,37)=4.33, p<0.02].
Morphine-induced locomotor activity
In agreement with previous findings (Giros et al., 1996), DAT-/- mice showed a pronounced
hyperlocomotion compared to the other two genotypes. Morphine pretreatment (5 mg/kg, s.c.)
stimulated locomotion in DAT+/+ and DAT+/- mice but not in DAT-/- mice [genotype:
F(2,95)=55.49, p<0.0001; treatment: F(1,95)=5.84, p<0.02; genotype x treatment interaction:
F(2,95)=12.21, p<0.0001] (Figure 2A). Post-hoc individual comparisons between morphine- and
saline-treated animals indicated a significant effect of morphine in DAT+/+ (p<0.001) and
DAT+/- (p<0.01) mice, but not in DAT-/- mice (n.s.). A higher dose of morphine (8 mg/kg, s.c.)
also failed to stimulate locomotion in DAT-/- mice, although it significantly increased horizontal
activity in both DAT+/+ and DAT+/- mice (not shown).
In the second experiment, mice were habituated to the activity boxes during 10 h for three
consecutive days. The saline challenge performed on day 4, after 8 h of habituation to the
activity cages, induced no significant effects on locomotor activity in any of the three genotypes
(data not shown). On day 5, DAT-/- mice were significantly hyperactive when compared to both
DAT+/+ and DAT+/- mice [genotype: F(2,28)=34.28, p<0.0001; time: F(7,203)=16.66,
p<0.0001; genotype x time interaction: F(14, 203)=7.72, p<0.0001] (Figure 2B). However, at
the time of morphine challenge, administered 8 h after the introduction of the animals in the
activity boxes, spontaneous activity was not significantly different in the three groups of mice at
the time of morphine injection [F(2,28)=1.75, n.s.] (Figure 2B). The administration of morphine
(5 mg/kg, s.c.) induced a strong increase in locomotion in DAT+/+ and DAT+/- mice, but did not
enhance the horizontal activity of DAT-/- mice [genotype: F(2,28)=5.02, p<0.015; time:
F(2,58)=37.63, p<0.0001; genotype x time interaction: F(4,58)=8.96, p<0.0001] (Figure 2B).
The lack of morphine-induced locomotion in DAT-/- mice was not the consequence of increased
stereotypies, as the three groups of mice exhibited diminished vertical activity after morphine
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injection (5 mg/kg, s.c.) [genotype: F(2,30)=5.05, p<0.02; time: F(2,62)=6.12, p<0.004;
genotype x time interaction: F(4,62)=5.48, p<0.001] (Figure 2C).
To exclude the possibility that DAT-/- mice might have been exhausted at the time of
morphine administration and were thus unable to respond to the motor stimulatory effect of the
drug, we measured the locomotion of DAT-/- mice in response to a natural arousal stimulus, i.e.,
the transition from light to dark. After 48 h of habituation to the activity boxes, DAT+/+ and
DAT-/- mice did not differ in their level of locomotion [F(1,15)=0.16, n.s.] (Figure 2D). At the
time of light to dark transition (19:30), DAT-/- mice exhibited a marked increase in locomotion
as compared to DAT+/+ controls [genotype: F(1,15)=4.33, p=0.056; time: F(2,32)=9.21;
p<0.001; genotype x time interaction: F(2,32)=3.23, p=0.054] (Figure 2D).
Morphine-induced analgesia
The function of opioid receptors was evaluated by investigating the analgesic responses to acute
morphine administration (5 mg/kg, s.c.) in DAT-/- mice. Morphine induced strong
antinociceptive effects in the three groups of mice as assessed in the hot-plate [paw licking,
genotype: F(2,94)=1.14, n.s.; treatment: F(1,94)=80.76, p<0.0001; genotype x treatment
interaction: F(2,94)=1.08, n.s.; and jumping, genotype: F(2,94)=9.66, p<0.001; treatment:
F(1,94)=342.23, p<0.0001; genotype x treatment interaction: F(2,94)=0.95, n.s.] and tail-
immersion [genotype: F(2,94)=0.93, n.s.; treatment: F(1,94)=41.19, p<0.0001; genotype x
treatment interaction: F(2,94)=0.89, n.s.] tests (Figure 3). Saline-treated DAT-/- mice displayed
an increased latency to jump compared to DAT+/+ mice. It is unlikely that this effect is related t o
a natural resistance of DAT-/- mice to the hot-plate test, since paw licking latency was unaffected
in saline-treated animals. The decreased jumping activity in DAT-/- mice could instead be related
to an inhibitory effect of the stress of the hot-plate test on the motor activity of these animals.
Indeed, we have previously observed that the hyperactivity of DAT-/- mice is reduced under
anxiogenic conditions (unpublished observation).
Naloxone-precipitated morphine withdrawal
After chronic morphine treatment, naloxone administration (1 mg/kg, s.c.) precipitated a
syndrome of abstinence identical in the three groups of mice for two physical signs, jumping and
wet dog shakes (Figure 4). Accordingly, the ANOVA showed a significant treatment effect for
jumping [F(1,80)=18.88, p<0.0001] and wet dog shakes [F(1,80)=88.88, p<0.0001], but neither a
genotype effect nor a  genotype x treatment interaction. Evaluation of the other signs of
withdrawal (sniffing, paw tremor, tremor, ptosis and teeth chattering) revealed a decrease of their
intensity in the DAT-/- mice as compared to DAT+/+ and DAT+/- mice [sniffing, genotype:
F(2,80)=2.64, p=0.07; treatment: F(1,80)=25.76, p<0.0001; interaction: F(2,80)=2.45, p=0.09;
paw tremor, genotype: F(2,80)=2.84, p=0.06; treatment: F(1,80)=83.43, p<0.0001; interaction:
F(2,80)=2.36, n.s.; tremor,  genotype: F(2,80)=6.16, p<0.003; treatment: F(1,80)=60.15,
p<0.0001; interaction: F(2,80)=3.79, p<0.03; ptosis,  genotype: F(2,80)=8.00, p<0.001;
treatment: F(1,80)=49.36, p<0.0001; interaction: F(2,80)=4.71, p<0.01; teeth chattering,
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genotype: F(2,80)=13.27, p<0.0001; treatment: F(1,80)=369.639, p<0.0001; interaction:
F(2,80)=11.07, p<0.0001] (Figure 4).
Morphine-induced DA release in the nucleus accumbens shell
We evaluated the effect of systemic morphine administration (5 mg/kg, s.c.) on DA release in the
AcbSh. The extracellular DA concentration was monitored in the AcbSh with carbon fiber
electrodes combined with differential normal pulse voltammetry. The recordings showed an
oxidation current peak appearing at the same potential as the DA oxidation peak (+85 mV), with
an amplitude proportional to the extracellular DA concentration in pargyline-treated mice. Thus,
in DAT+/+, DAT+/- and DAT-/- mice treated with pargyline, the catechol oxidation peak
appearing at +85mV entirely corresponded to extracellular DA, as previously demonstrated in rats
(Gonon & Buda, 1985). Indeed, this peak appeared at the DA oxidation potential and was related
to dopaminergic innervation since it was not observed in brain regions poorly innervated by DA
terminals (e.g., frontal cortex, data not shown). Moreover, in these mice as well as in normal rats
(Gonon & Buda, 1985), this peak was immediately and reversibly enhanced by electrical
stimulation of the MFB (4 Hz for 40 s, data not shown). Therefore, in all genotypes, the
amplitude of this catechol peak was converted into DA concentration by in vitro calibration after
in vivo recordings.
One hour after morphine administration, this peak was enhanced in the same proportion in
both DAT+/+ and DAT-/- mice (Figure 5A). Consistent with previous observations in the striatum
(Jones et al., 1998), the basal extracellular DA concentration was one order of magnitude higher
in the AcbSh of DAT-/- mice than in DAT+/+ and DAT+/- mice [F(2,16)=42.68, p<0.0001]
(Figure 5B). Morphine administration more than doubled the extracellular DA concentration in
the AcbSh of DAT+/+ mice, compared to vehicle-treated mice [F(1,8)=8.86, p<0.02]; DAT+/-
and DAT-/- mice also exhibited enhanced DA levels after morphine administration
[F(25,325)=40.26, p<0.0001] (Figure 5B). Importantly, DA levels in DAT-/- mice were increased
(+158 %) in the same proportion as in DAT+/+ mice (+165%). Consequently, morphine
administration brought the extracellular DA level in DAT-/- mice up to more than 20 times the
basal level observed in DAT+/+ mice.
In order to elucidate the mechanisms implicated in the accumulation of such high levels of
DA in the extracellular fluid in DAT-/- mice, we recorded DA overflow evoked by electrical
stimulation of the MFB. This overflow resulted from the evoked DA release minus DA
elimination. In the AcbSh of DAT+/+ mice (Figure 5C), DA elimination was as fast as that
reported in the rat AcbSh, due to the reuptake by dopaminergic terminals (Dugast et al., 1994).
Accordingly, with stimulation at 4 Hz, the DA released by one pulse was completely eliminated
before the next pulse (Figure 5C). In contrast, in DAT-/- mice, the elimination of extracellular
DA was slowed down by almost two orders of magnitude, in agreement with previous in vitro
observations in the striatum (Jones et al., 1998). Therefore, the released DA which accumulated
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with successive pulses at 4 Hz in DAT-/- mice produced a much higher extracellular DA level with
prolonged stimulation despite a smaller DA release per pulse (Figure 5C).
Morphine administration enhances DA release in AcbSh by doubling the firing rate of ventral
tegmental area DA neurons (Di Chiara & North, 1992). Our results show that in both DAT+/+
and DAT-/- mice, electrical stimulation at 4 Hz, which mimics the increase in discharge rate,
induced a DA overflow in the AcbSh with an amplitude similar to that observed after morphine
administration (compare C and B in Fig. 5).
c-fos in situ hybridization
Figure 6 shows morphine-induced transcription of the immediate early gene c-fos in DAT-/- and
wild-type mice. One hour after administration of morphine (5 mg/kg, s.c.), the expression of c-fos
mRNA was increased in the dorsomedian caudate-putamen, the AcbSh and the cingulate cortex in
both DAT+/+ and DAT-/- mice compared to saline-treated controls [dorsomedian caudate-
putamen: F(3,13)=3.59, p<0.054; AcbSh: F(3,13)=39.58, p<0.001; and cingulate cortex:
F(3,13)=3.73, p<0.05]. The increase in c-fos mRNA transcription was higher in DAT-/- mice
(+950%) than in DAT+/+ mice (+615%), specifically in the AcbSh (p<0.001) as compared t o
other brain structures such as the caudate-putamen and the cingulate cortex (Figure 6). The
experiment was replicated twice, and similar results were obtained each time.
µ opioid receptor autoradiography
We then investigated possible adaptive changes in the opiate system of the mutant mice at the
cellular level. Quantitative autoradiography with the µ opioid receptor selective radioligand
[125I]FK-33824 revealed no changes in µ opioid receptor levels in the striatum, the nucleus
accumbens and ventral tegmental area of DAT-/- mice as compared to control littermates (Figure
7).
Discussion
The aim of this study was to investigate the behavioral responses related to opioid addiction in
DAT-/- mice characterized by a constitutive elevation of DA mesolimbic transmission. Morphine
induced an increased conditioned place preference in DAT-/- mice in the place preference test, but
failed to stimulate locomotor activity. Moreover, morphine withdrawal physical symptoms were
decreased in DAT-/- mice compared to control animals. The voltammetry studies revealed that
morphine administration was able to activate the mesolimbic DA pathway in DAT-/- mice,
thereby resulting in a dramatic increase in the level of extracellular DA. Finally, an enhancement
of morphine-induced c-fos transcription was observed in the AcbSh, although no compensatory
changes at the level of µ opioid receptors were observed in the mutant mice.
The rewarding properties of morphine were examined using a conditioned place preference
task. This procedure has been found to be sensitive to the rewarding or aversive effects of a
number of abused drugs (for review, see Carr et al., 1989), including morphine (Mucha et al.,
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1982; Mucha & Iversen, 1984; Vezina & Stewart, 1987), and has the advantage of examining the
conditioned rewarding effects in a drug-free state. Used for several years in rats, the conditioned
place preference task has recently been adapted to mice, and DAT-/- mice have already been
shown to respond to the conditioned reward properties of cocaine in this test (Sora et al., 1998).
Our results showed that DAT-/- mice exhibited an increased place preference in response t o
morphine as compared to control littermates. This finding suggests that despite the profound
modifications of DA neurotransmission present in these mice (Giros et al., 1996; Jones et al.,
1998), the stimulating action of morphine on the firing of DA neurons was not impaired, allowing
the expression of morphine reward. The increased morphine-induced stimulus-reward conditioning
in DAT-/- mice could be associated to increased drug sensitivity or faster conditioned place
preference acquisition, although at present we can not differentiate between these two
possibilities. The implication of DA neurotransmission in the mediation of the rewarding
properties of morphine is controversial. Indeed, while opioid-induced place preference has been
reported to be decreased by DA D2 receptor-preferring neuroleptics, D1 receptor antagonists, D3
receptor agonists and neurotoxin lesions of DA pathways, other studies failed to observe an
impairment of opioid place preference using the preferential D2 receptor antagonist alpha-
flupentixol and the selective D2 receptor antagonist sulpiride (for reviews, see Di Chiara, 1995;
Shippenberg & Elmer, 1998). Furthermore, microinjections of morphine into either the ventral
tegmental area, the region containing the cell bodies of mesolimbic DA neurons, or the nucleus
accumbens, the terminal region of mesolimbic DA neurons, produced marked place preference,
highlighting the possibility of DA-dependent and DA-independent mechanisms (see Stinus et al.,
1992; Shippenberg & Elmer, 1998). Under our experimental conditions, haloperidol (0.15 mg /kg,
i.p.) administered 40 min before the test, reversed morphine-induced place preference in DAT-/-
mice and control animals (data not shown). However, this dose of haloperidol was strongly
aversive by itself, thus precluding any clear conclusion concerning the DA-dependency of the
rewarding effects of morphine. Additional studies are needed in order to clarify this issue.
In DAT-/- mice, the overstimulation of DA neurotransmission is associated with low levels
of endogenous DA and down-regulation of post-synaptic DA receptors (Giros et al., 1996; Jones
et al., 1998). Therefore, it was interesting to evaluate under these particular conditions, the
ability of morphine to activate DA mesolimbic neurons. Using in vivo voltammetry, we measured
the effect of systemic morphine administration (5 mg/kg, s.c.) on DA extracellular levels in the
AcbSh, a brain structure in which DA transmission is strongly sensitive to opioid stimulating
action (Di Chiara & Imperato, 1988; Pontieri et al. , 1995). In agreement with previous
observations in the striatum (Jones et al., 1998), we confirmed that the basal extracellular DA
concentration in the AcbSh was one order of magnitude higher in DAT-/- mice than in DAT+/+
and DAT+/- mice. Our results demonstrate that morphine was still able to activate the mesolimbic
DA pathway in DAT-/- mice, resulting in an excessively high level of extracellular DA, which
cannot be reached in DAT+/+ and DAT+/- mice because of DA reuptake. Interestingly, the
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percentage increase of morphine-induced DA release was similar in DAT+/+ and DAT-/- mice,
despite a DA content in dopaminergic terminals which is dramatically reduced in DAT-/- mice
(Jones et al., 1998). This could be explained by the high DA synthesis rate observed in DAT-/-
mice (Jones et al., 1998). In addition, the ability of morphine to stimulate DA neurons in the
presence of elevated extracellular DA concentrations could be related to the loss of DA D2
autoreceptor function recently reported in DAT-/- mice (Jones et al., 1999). Furthermore, these
findings indicate that the activation of µ opioid receptors, the main target for morphine action
(Shippenberg et al., 1988; Corbett et al., 1993; Matthes et al., 1996; Piepponen et al., 1997), is
sufficient to increase DA release in the AcbSh of DAT-/- mice. Our results suggest that no
compensatory mechanism due to the knockout occurred in the expression and/or function of µ
opioid receptors. This was actually confirmed by the results of autoradiography binding and
morphine-induced analgesia experiments. Whether morphine-induced DA release in the AcbSh of
DAT-/- mice is associated with the potentiating action of the drug during the conditioning phase
of the place preference task remains to be established. However, when treated with cocaine, a drug
that is unable to induce an increase in extracellular DA in DAT-/- mice, the mutant mice exhibit a
reward response of equal magnitude to that of DAT+/+ mice (Rocha et al., 1998). Therefore, the
increased extracellular level of DA induced by morphine in DAT-/- mice could be related t o
increased rewarding properties of the drug.
In contrast, morphine was unable to stimulate locomotion in DAT-/- mice, whether
administered at a motor active or inactive state, although the mice clearly responded with
increased locomotor activity to a natural arousal stimulus, the transition from light to dark
period. As for the conditioned place preference test, the role of DA in morphine-induced
locomotion is controversial and both DA-dependent and DA-independent mechanisms have been
proposed. Microinjections of morphine into the nucleus accumbens elicit an hyperlocomotion,
which is enhanced after chronic impairment of DA transmission following the administration of
DA receptor antagonists or neurotoxin lesions (Kalivas et al., 1983; Stinus et al., 1985; Di Chiara,
1995). The inability of morphine to induce locomotion in DAT-/- mice cannot be explained by
altered expression of µ opioid receptors, an important target for morphine locomotor stimulating
action (Michael-Titus et al., 1989; Piepponen et al., 1999), since, as mentioned previously,
[125I]FK-33824 autoradiography revealed normal density and distribution of these receptors in
DAT-/- mice. This was further stressed by the observation that acute morphine was able t o
decrease the vertical activity of DAT-/- mice, an effect also mediated by µ opioid receptor
activation (Michael-Titus et al., 1989; Mickley et al., 1990). The lack of morphine-induced
locomotion in DAT-/- mice is particularly intriguing considering that it has been widely assumed
that the increase in extracellular DA in the nucleus accumbens induced by drugs of abuse is
associated with a stimulation of DA-dependent locomotion, which is predictive of the abuse
liability of the drug (Wise & Bozarth, 1987). The psychomotor stimulant theory was not
confirmed in the present study, since DAT-/- mice exhibited a dissociation between the rewarding
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and locomotor responses to morphine. DAT-/- mice also show a dissociation between the
rewarding and locomotor properties of cocaine (Giros et al., 1996; Sora et al., 1998). Similarly, a
recent study using mice lacking DA D2 receptors reported an absence of morphine rewarding
effects while the locomotor stimulating action of the drug remained intact (Maldonado et al.,
1997). These results, together with the findings of the present study, suggest that under particular
genetic conditions, the psychomotor stimulant theory is not always applicable.
Investigation of morphine-induced c-fos transcription in the brain of DAT-/- and DAT+/+
mice revealed that the activation of c-fos in the AcbSh was stronger in mutant mice. The AcbSh
has been reported to exhibit the highest increase in fos-like protein expression in response t o
morphine administration, as compared to the core region of the nucleus accumbens and the
dorsolateral striatum (Liu et al., 1994; Barrot et al., 1999). This regional specificity is evident
after morphine activation, but appears to be less clear after cocaine administration (Barrot et al.,
1999). Together with the results of the voltammetry study, our data are in agreement with ample
evidence demonstrating a converging action of DA and opioid systems at the molecular level of
neurons located in the nucleus accumbens (Nestler et al., 1993; Bontempi & Sharp, 1997; Nestler
& Aghajanian, 1997). The contribution of DA in morphine-induced c-fos expression in DAT-/-
mice is further supported by the fact that cocaine, which action on extracellular DA
concentration is abolished in DAT-/- mice, does not induce c-fos mRNA expression in the nucleus
accumbens of mutant mice (Rocha et al., 1998). Transcription of immediate early genes following
morphine administration represents a molecular basis for long-term behavioral changes (Nestler et
al., 1993; Nestler et al., 1996). Thus, the sensitization of the c-fos response may play a key role
in the differential sensitivity to morphine observed in DAT-/- vs. DAT+/+ mice. However, as in
the case of other knockout mice, we cannot exclude specific adaptive processes that could have
occurred during the development of DAT-/- mice and that may be partly responsible for the
observed phenotype.
The investigation of the somatic expression of morphine abstinence in DAT-/- mice
revealed that most physical signs of morphine withdrawal were blunted in mutant mice, supporting
the participation of the DA system in the alleviation of these behaviors. Activation of D2
receptors within the nucleus accumbens has been reported to prevent the somatic signs of
naloxone-induced opioid withdrawal (Harris & Aston-Jones, 1994), although this brain region has
been mainly implicated in mediating the motivational aversive stimulus properties of opioid
withdrawal (Koob, 1992). The results of Harris & Aston-Jones (1994) have not been replicated
and a recent study using D2 receptor deficient mice did not report any changes in the physical
component of opioid dependence (Maldonado et al., 1997), thus questioning the specific
participation of D2 receptors in the abstinence syndrome. The alleviation of morphine abstinence
signs we observed in DAT-/- mice may rather be related to changes induced by altered DA
neurotransmission in the opioid systems or related neurotransmitters implicated in the physical
signs of morphine withdrawal.
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In conclusion, in the present work we demonstrated that genetically modified mice with an
altered DA neurotransmission showed differential sensitivity to the rewarding and locomotor
activating properties of morphine. We also revealed that despite the DA-deficient but
functionally hyperactive DA neurotransmission present in DAT-/- mice, morphine administration
was still able to increase DA levels in the nucleus accumbens, which could participate in the long
term changes at a molecular level. These results further support the role of DA in opioid
addiction, especially concerning the involvement of the imbalance of aminergic transmission in
the etiology of substance abuse.
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Figure 1. Morphine-induced conditioned place preference in DAT+/+, DAT+/- and DAT-/- mice.
(A) Time spent in the drug-associated compartment during the pre-conditioning and the post-
conditioning sessions in saline (SAL) and morphine (MOR; 5 mg/kg, s.c.) treated mice. (B) Scores
calculated as the difference (in seconds) between post-conditioning and pre-conditioning time
spent in the compartment associated with the drug in saline and morphine-treated mice. Data
represent mean ± SEM; DAT+/+, n=15-16; DAT+/-, n=12-14; and DAT-/-, n=6-8. Results were
analyzed by an ANOVA; post-hoc individual comparisons were made using the Student's t-test. *
P<0.05 and ** P<0.01 vs. saline-treated mice of the same genotype; #  P<0.05 vs. morphine-
treated DAT+/+ and DAT+/- mice.
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Figure 2. Effect of acute morphine administration on locomotor activity in DAT+/+, DAT+/- and
DAT-/- mice. (A) Morphine (5 mg/kg, s.c.), administered 10 min before introducing mice in the activity
boxes, failed to stimulate locomotor activity in DAT-/- mice. Values represent mean ± SEM locomotor
activity during a 10 min test; DAT+/+, n=18; DAT+/-, n=22-23; DAT-/-, n=7-9. Data were analyzed by
a two-way ANOVA, followed by post-hoc Student’s t-test. ** P<0.01 and *** P<0.001 vs. saline-
treated mice of the same genotype; ## P<0.01 and ### P<0.001 vs. DAT+/+ and DAT+/- mice
receiving the same treatment. (B) Morphine (5 mg/kg, s.c.) failed to induce locomotor activation in
DAT-/- mice on the 5th day of the experiment, after 4 days of habituation to the activity boxes. Values
represent mean ± SEM (n= 9-11). ** P<0.01 and *** P<0.001 vs. DAT+/+ and DAT+/- mice at the
same time point; # P<0.05 vs. DAT+/- mice at the same time point. (C)  Vertical activity after
morphine administration (5 mg/kg s.c.) was recorded on the 5th day of the experiment, in parallel with
the locomotor activity shown in B. Values represent mean ± SEM (n=9-11) of rearing activity one hour
before and two hours after the injection of morphine. * P<0.05 and *** P<0.001 vs. basal vertical
activity before morphine; ## P<0.001 vs. DAT+/+ and DAT+/- mice. (D) Locomotor activity during
the light to dark transition in DAT-/- mice and DAT+/+ littermates. Values represent mean ± SEM
(n=6-10). * P<0.05 vs. DAT+/+ mice at the same time point.
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Figure 3. Morphine-induced analgesia in DAT+/+, DAT+/- and DAT-/- mice in the tail-
immersion and hot-plate tests. Mice were injected with morphine (5 mg/kg, s.c., black bars) or
saline (white bars) and their analgesic responses were evaluated 30 min later. Results are expressed
as the latency (in sec) for tail withdrawal, licking and jumping. Values represent mean ± SEM
(n=8-22). Data were analyzed by a two-way ANOVA, followed by post-hoc Student’s t-test. *
P<0.05 and *** P<0.001 vs. saline-treated mice of the same genotype; ## P<0.01 vs. DAT+/+
mice receiving the same treatment.
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Figure 4. Behavioral signs of abstinence during naloxone-precipitated morphine withdrawal
syndrome in DAT+/+, DAT+/- and DAT-/- mice. Values represent mean ± SEM (n=6-16). Values
were analyzed by a two-way ANOVA, followed by Student's t-test. * P<0.05, ** P<0.01 and ***
P<0.001 vs. saline-treated mice of the same genotype; # P<0.05,## P<0.01 and ### P<0.001 vs.
DAT+/- and DAT+/+ mice receiving the same treatment.
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Figure 5. Effect of morphine and of electrical stimulation of the medial forebrain bundle (MFB)
on extracellular DA concentration in the shell of the nucleus accumbens (AcbSh) in DAT+/+,
DAT+/- and DAT-/- mice. (A) Differential normal pulse (DNP) voltammograms were recorded
every 90 s using carbon fiber electrodes implanted in AcbSh of pargyline-treated mice. One hour
after morphine administration (5 mg/kg, s.c.), the oxydation current peak was enhanced in the
same proportion in both DAT+/+ and DAT-/- mice. The photomicrograph shows the
implantation site of a carbon fiber electrode in the AcbSh (arrow). In order to reveal the site of
implantation after recording, the tissue was lesioned around the active part of the electrode by
applying a +5V current for 2 s. (B) After basal recording for 30 min, morphine (5 mg/kg, s.c.) was
administered to DAT+/+, DAT+/- and DAT-/- mice and vehicle to DAT+/+ mice. The
extracellular DA concentration was estimated from the amplitude of the DA oxidation peak
(mean ± SEM; n=4 mice per group). (C)  Electrical stimulation (4 Hz) of the dopaminergic
pathway in the MFB was applied for 50 pulses (top panel) or 4 pulses (bottom panel) and the
evoked variations in the extracellular DA concentration were recorded by a carbon fiber electrode
combined with amperometry.
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Figure 6. Morphine-induced c-fos expression in the brain of DAT+/+ and DAT-/- mice. Acute
morphine (MOR; 5 mg/kg, s.c.) increased the expression of c-fos mRNA in the dorsomedian
caudate putamen (Cpu), the shell of the nucleus accumbens (AcbSh) and the cingulate cortex (Cg
Cx) in both DAT+/+ and DAT-/- mice. c-fos transcription in the AcbSh was higher in DAT-/-
mice than in control mice, whereas no differences were observed in the CPu and the Cg Cx.
Results are expressed as arbitrary units (mean ± SEM; n=4 per group). Values in saline- vs.
morphine-treated DAT+/+ were: Cpu, 100 ± 26.34 vs. 358.74 ± 77.15; AcbSh, 153.93 ± 41.40
vs. 1101.07 ± 99.63; Cg Cx, 1218.44 ± 115.19 vs. 2139.78 ± 153.97; and in saline- vs.
morphine-treated DAT-/- mice: Cpu, 159.37 ± 29.47 vs. 314.54 ± 110.23; AcbSh, 208.06 ±
56.27 vs. 2179.60 ± 260.10; Cg Cx, 1126.92 ± 293.43 vs. 1898.73 ± 234.65. Data were analyzed
by one-way ANOVA followed by post-hoc Newman-Keuls test. * P<0.05, ** P<0.01 and ***
P<0.001 vs. saline-treated mice of the same genotype; ### P<0.001 vs. DAT+/+ mice receiving
the same treatment.
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Figure 7. µ opioid receptor autoradiography in the brain of DAT+/+ and DAT-/- mice. Iodinated
FK-33824 binding was quantified by densitometry at different brain levels and converted t o
nCi/mg protein. Values in DAT+/+ and DAT-/- mice were: in the striatum (Cpu), 9706 ± 2531 vs.
12132 ± 1455; in the accumbens (Acb), 13415 ± 2547 vs. 14353 ± 3299; and in the ventral
tegmental area (VTA), 6758 ± 1216 vs. 6555 ± 1114. Values are shown as percentage of binding
observed in DAT+/+ mice (mean ± SEM; n=7 mice per group).
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